Synergy Pharmaceuticals Reaches Halfway Mark For The First Pivotal Phase 3 Trial Of Plecanatide In Patients With Chronic Idiopathic Constipation
7/14/2014 11:29:06 AM
NEW YORK--(BUSINESS WIRE)--Synergy Pharmaceuticals Inc. (NASDAQ:SGYP) today announced that it has reached the halfway mark for total enrollment in the first pivotal phase 3 trial of plecanatide in patients with chronic idiopathic constipation (CIC).
Help employers find you! Check out all the jobs and post your resume.
comments powered by